Want to see HK:1530 full AI Analyst Report?
1530 Stock Chart & Stats
HK$16.96
HK$0.34(1.98%)
At close: 4:00 PM EDT
HK$16.96
HK$0.34(1.98%)
Day’s Range― - ―
52-Week RangeHK$14.81 - HK$35.42
Previous CloseN/A
Volume13.82M
Average Volume (3M)18.35M
Market Cap
HK$39.85B
Enterprise ValueHK$28.64B
Total Cash (Recent Filing)HK$17.59B
Total Debt (Recent Filing)HK$666.81M
Price to Earnings (P/E)3.9
Beta0.81
Next Earnings
Mar 30, 2027EPS Estimate
0.57Next Dividend Ex-DateN/A
Dividend Yield1.67%
Share Statistics
EPS (TTM)3.32
Shares Outstanding2,538,321,000
10 Day Avg. Volume14,612,290
30 Day Avg. Volume18,350,672
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.97
Price to Sales (P/S)3.03
P/FCF Ratio5.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$29.35Price Target Upside73.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)0.95
Revenue Forecast (FY)HK$9.40B
Bulls Say, Bears Say
Bulls Say
Sharp 2025 Revenue And Profit AccelerationThe sharp 2025 revenue increase, combined with exceptionally high gross, operating, and net margins, indicates strong commercial scaling and substantial earnings capacity. If these results persist, the improved profitability can support continued investment, strengthen the company’s position in biopharmaceutical markets, and enhance internal funding for growth.
Improved Balance-sheet ResilienceThe materially lower debt-to-equity ratio gives 3SBio a more conservative financial structure and greater resilience than in prior years. Reduced leverage can limit balance-sheet pressure while the company scales, preserve flexibility for operating needs, and make strong returns on expanded equity and assets more durable.
Strong 2025 Cash GenerationOperating and free cash flow closely tracking net income provides evidence that the sharp earnings improvement was supported by cash generation rather than accounting profit alone. This strengthens funding for research, commercialization, and other business needs while reducing reliance on external financing over coming quarters.
Bears Say
Volatile Revenue Growth HistoryThe uneven performance before 2025 makes it harder to establish that the latest growth step-change represents a stable underlying trend. Such variability can complicate planning and increase the risk that future revenue expansion depends on factors that do not repeat consistently across reporting periods.
Uncertain Sustainability Of Exceptional MarginsThe substantial swing in profitability across recent years raises a durability question around the 2025 margin level. If margins normalize toward earlier outcomes, earnings growth could materially slow even if product sales continue expanding, reducing confidence in the persistence of current earnings power.
Historically Inconsistent Cash ConversionEarlier periods of weaker cash conversion show that reported earnings have not always translated into equivalent cash generation. This variability can create working-capital or cash-timing pressure and makes internally funded expansion less predictable, despite the much stronger cash profile reported for 2025.
3SBio News
1530 FAQ
What was 3SBio’s price range in the past 12 months?
3SBio lowest stock price was HK$14.81 and its highest was HK$35.42 in the past 12 months.
What is 3SBio’s market cap?
3SBio’s market cap is HK$39.85B.
When is 3SBio’s upcoming earnings report date?
3SBio’s upcoming earnings report date is Mar 30, 2027 which is in 172 days.
How were 3SBio’s earnings last quarter?
3SBio released its earnings results on Aug 20, 2026. The company reported HK$0.515 earnings per share for the quarter, missing the consensus estimate of HK$0.749 by -HK$0.234.
Is 3SBio overvalued?
According to Wall Street analysts 3SBio’s price is currently Undervalued.
Does 3SBio pay dividends?
3SBio pays a Annually dividend of HK$0.25 which represents an annual dividend yield of 1.67%. See more information on 3SBio dividends here
What is 3SBio’s EPS estimate?
3SBio’s EPS estimate is 0.57.
How many shares outstanding does 3SBio have?
3SBio has 2,538,321,000 shares outstanding.
What happened to 3SBio’s price movement after its last earnings report?
3SBio reported an EPS of HK$0.515 in its last earnings report, missing expectations of HK$0.749. Following the earnings report the stock price went down -1.138%.
Which hedge fund is a major shareholder of 3SBio?
Currently, no hedge funds are holding shares in HK:1530
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
3SBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.84%
12-Months-Change
Fundamentals
Return on Equity
30.16%
Trailing 12-Months
Asset Growth
57.66%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
3SBio
Operating as an investment holding company, 3SBio Inc. specializes in the full lifecycle of biopharmaceutical products within the People's Republic of China, encompassing research, development, manufacturing, marketing, and sales. Its diverse portfolio addresses a range of medical needs. Key therapeutic agents include TPIAO, a recombinant human thrombopoietin for chemotherapy-induced and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; and recombinant human erythropoietins EPIAO and SEPO, along with Aiyishu, to combat various forms of anemia. In oncology, Cipterbin is used for HER2-positive metastatic breast cancer in combination with chemotherapy. Intefen, a recombinant human interferon, targets lymphatic or hematopoietic malignancies and viral infections, while Inleusin, a human interleukin-2, treats renal cell carcinoma, melanoma, and thoracic fluid build-up. The company also offers Mandi for male alopecia and alopecia areata; Xenopax to prevent acute rejection post-renal transplant; Byetta for glycemic control in type 2 diabetes patients; and Qiming Keli for retinopathy linked to type 2 diabetes. SPARIN, an injectable low-molecular-weight heparin calcium, serves in the prophylaxis and treatment of deep vein thrombosis, and prevents clotting during hemodialysis. Beyond its core pharmaceutical activities, 3SBio Inc. provides additional services such as trading, project management and consultation, technology, and agricultural support. The company maintains strategic alliances with numerous prominent organizations, including AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and the Dana–Farber Cancer Institute. Established in 1993, its headquarters are situated in Shenyang, People's Republic of China.
1530 Stock 12 Month Forecast
Average Price Target
HK$29.35
▲(73.03% Upside)
Technical Analysis
Wuxi Biologics (Cayman)
―
Akeso, Inc.
―
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―